Lou Reese - 07 Mar 2023 Form 4 Insider Report for Vaxxinity, Inc.

Role
Executive Chairman., Director
Signature
/s/ Rene Paula Molina as Attorney-in-Fact for Lou Reese
Issuer symbol
VAXX on OTC
Transactions as of
07 Mar 2023
Net transactions value
$0
Form type
4
Filing time
05 Apr 2023, 16:48:09 UTC
Previous filing
21 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VAXX Stock Option (right to buy) Award $0 +620,000 $0.000000 620,000 07 Mar 2023 Class A Common Stock 620,000 $2.29 Direct F1
transaction VAXX Stock Option (right to buy) Award $0 +61,607 $0.000000 61,607 07 Mar 2023 Class A Common Stock 61,607 $2.29 Direct F2
transaction VAXX Stock Option (right to buy) Award $0 +301,188 $0.000000 301,188 07 Mar 2023 Class A Common Stock 301,188 $2.29 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 48 equal monthly installments beginning on March 7, 2023.
F2 The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options are fully vested upon issuance. This one-time option grant was made in lieu of an annual cash bonus payment to Mr. Reese.
F3 The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 12 equal monthly installments beginning on January 1, 2023. The one-time option grant was made in consideration of Mr. Reese waiving his salary for fiscal years 2022 and 2023.

Remarks:

Executive Chairman.